Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial

The Lancet Infectious Diseases

Volumn 13, Issue 7, 2013, Pages 597-605

  Sulkowski, Mark ^a   Pol, Stanislas ^b   Mallolas, Josep ^c   Fainboim, Hugo ^d   Cooper, Curtis ^e   Slim, Jihad ^f   Rivero, Antonio ^g   Mak, Carmen ^h   Thompson, Seth ^h   Howe, Anita YM ^h   Wenning, Larissa ^h   Sklar, Peter ^h   Wahl, Janice ^h   Greaves, Wayne ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL F J MUÑIZ   (Argentina)

^e UNIVERSITY OF OTTAWA   (Canada)

^f ST MICHAEL S MEDICAL CENTER   (United States)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BOCEPREVIR; DARUNAVIR; FOSAMPRENAVIR; LOPINAVIR; MK 3034; PEGINTERFERON ALPHA2B; PLACEBO; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STEADY STATE; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PLACEBOS; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84879795434     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70149-X     Document Type: Article

References (19)

1. Staples CT, Rimland D, Dudas D Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
2. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805. for the Swiss HIV Cohort Study.
3. Denis F Seroprevalence of HBV, HCV and HDV hepatitis markers in 500 patients infected with the human immunodeficiency virus. Pathol Biol (Paris) 1997, 45:701-708.
4. Naggie S, Sulkowski MS Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012, 142:1324-1334.
5. Sulkowski MS Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 2013, 207(Suppl 1):S26-S32.
6. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50:407-413.
7. Berenguer J, Rodríguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012, 55:728-736.
8. Pol S, Soriano V Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008, 47:94-101.
9. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004, 18:F27-F36.
10. Rodriguez-Torres M, Slim J, Bhatti L, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012, 13:142-152.
11. Poordad F, Bacon B, Bruno S, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
12. Bacon B, Gordon S, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
13. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013, 56:718-726.
14. Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis c virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013, 56:1646-1653.
15. Berenguer J, Alvarez-Pellicer J, Carrero A, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol 2013, 58:1104-1112.
16. Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R Treatment for hepatitis C virus infection in adults 2012, US Agency for Healthcare Research and Quality, Rockville, MD.
17. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
18. de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013, 56:300-306.
19. Black S, McMonagle P, Chase R, et al. HCV NS3/4A protease resistance-associated variants (RAVs) identified in genotype 1a patients exhibit differences in phenotypic resistance to boceprevir and telaprevir in genotype 1a replicon cells (poster 1198). J Hepatol 2012, 56(suppl 2):S475.